Kedudukan dalam Saham
#38812
Redx Pharma Plc, established in the United Kingdom in 2010 and headquartered in... Redx Pharma Plc, established in the United Kingdom in 2010 and headquartered in Macclesfield, concentrates its efforts on the discovery, early-stage preclinical development, and licensing of innovative small molecule drugs. The company primarily targets significant unmet medical needs in the therapeutic areas of oncology and fibrosis. Within its oncology portfolio, Redx is progressing RXC004, a porcupine inhibitor currently undergoing Phase II clinical evaluation for treating cancers driven by Wnt-ligands. Additionally, it maintains a research collaboration with Jazz Pharmaceuticals plc, aiming to identify and advance new drug candidates for two specific cancer pathways: the Ras/Raf/MAP kinase pathway. For fibrotic conditions, Redx Pharma is developing several compounds, including RXC007, an oral selective ROCK2 inhibitor intended for the treatment of various fibrotic diseases. Its pipeline also features a gastrointestinal-targeted ROCK inhibitor specifically designed to address fibrosis associated with Crohn's disease, along with a discoidin domain receptors (DDRs) inhibitor for a range of fibrotic disorders. Furthermore, the company is developing RXC006, another porcupine inhibitor, focused on combating fibrotic illnesses such as idiopathic pulmonary fibrosis.
Harga Saham
$0.20410523
Disegerakkan terakhir: 2024-04-30
Perubahan (1 hari)
42.54%
Perubahan (1 tahun)
0.00%
Perdagangan Redx Pharma Plc (REDX)
Hasil untuk Redx Pharma Plc (REDX)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Redx Pharma Plc, hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Redx Pharma Plc dari 2026 hingga 2026
Hasil pada akhir setiap tahun
| Tahun |
Hasil |
Ubah |
|
Tidak cukup data untuk tarikh yang disediakan. |
Hasil untuk syarikat atau pesaing serupa
| Syarikat |
Hasil |
Perbezaan Hasil |
Negara |
|
|
$12.62B |
-
|
US
|
|
|
$6.02B |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
- |
-
|
KR
|
|
|
$10.11B |
-
|
BE
|
